Finance

Lists
Why is RMD down 2.33%?
Dive Deeper
RMD:NYSE
Resmed Inc
$234.87
-2.33%
(-5.60) 1D
Nov 5, 2:01:26 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RMD...
Open
$245.29
High
$246.68
Low
$233.12
Mkt. cap
33.04B
Avg. vol.
1.26M
Volume
703.33K
Dividend
1.12%
Quarterly dividend
$0.66
Ex-dividend date
Aug 20, 2026
P/E ratio
21.39
52-wk high
$277.67
52-wk low
$180.26
EPS
$10.98
Beta
0.77
Shares outstanding
140.66M
No. of employees
11K
Open
$245.29
High
$246.68
Low
$233.12
Mkt. cap
33.04B
Avg. vol.
1.26M
Volume
703.33K
Dividend
1.12%
Quarterly dividend
$0.66
Ex-dividend date
Aug 20, 2026
P/E ratio
21.39
52-wk high
$277.67
52-wk low
$180.26
EPS
$10.98
Beta
0.77
Shares outstanding
140.66M
No. of employees
11K
News stories
From web sources and news partners
Profile
Resmed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19. Resmed also provides software to out-of-hospital care agencies to streamline transitions of care into and between these care settings for seniors and their care providers. Resmed employs more than 8,000 people worldwide as of June 2022. The company operates in more than 140 countries worldwide, and has manufacturing facilities in Australia, Singapore, France, and the United States. Revenue was US$4.7 billion in fiscal year 2024. Wikipedia
About Resmed Inc
CEOMichael J. Farrell
Employees11.4K
FoundedJun 1989
HeadquartersSan Diego, California, United States
SectorHealth Care
IndustryMedical device
Websiteresmed.com
Analyst ratings
Based on 14 analysts giving stock ratings to RMD in the past 3 months
Buy
Buy
5
Hold
9
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for RMD in the last 3 months.
Highest
Current $234.87
$320.00 (+36.25%)
Average
$261.73 (+11.44%)
Lowest
$230.00 (-2.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lyanne Harrison
Bank of America Securities
Buy
Reiterated
$320.00
+36.2%
11/02/2026
Laura Sutcliffe
Citi
Hold
Maintained
$270.00
+15%
11/02/2026
David Bailey
Morgan Stanley
Hold
Maintained
$233.00
-0.8%
10/30/2026
Michael Matson
Needham
Hold
Maintained
-
-
10/30/2026
Adam Maeder
Piper Sandler
Hold
Maintained
$260.00
+10.7%
10/30/2026
Craig Wong-Pan
RBC Capital
Buy
Maintained
$288.00
+22.6%
10/30/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$270.00
+15%
10/30/2026
David Rescott
Robert W. Baird
Hold
Maintained
$246.00
+4.7%
10/30/2026
Nathan Treybeck
Wells Fargo
Hold
Reiterated
$250.00
+6.4%
10/30/2026
Brett Fishbin
KeyBanc
Buy
Maintained
$277.00
+17.9%
10/30/2026
Jonathan Block
Stifel Nicolaus
Hold
Maintained
$235.00
+0.1%
10/02/2026
Jackson Philips
Rothschild & Co Redburn
Hold
Initiated
$230.00
-2.1%
08/19/2026
Unknown Analyst
Oppenheimer
Hold
Reiterated
-
-
08/07/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
08/07/2026
Matthew Taylor
Jefferies
Hold
Maintained
$225.00
-4.2%
07/10/2026
Unknown Analyst
Jefferies
Hold
Reiterated
$225.00
-4.2%
07/10/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
$227.00
-3.4%
05/01/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
-
-
04/15/2026
Chris Cooper
J.P. Morgan
Buy
Initiated
-
-
04/15/2026
Unknown Analyst
Evercore ISI
Buy
Maintained
$255.00
+8.6%
04/13/2026
Larry Biegelsen
Wells Fargo
Hold
Maintained
$270.00
+15%
01/30/2026
Mark Wilson CFA
RBC Capital
Buy
Maintained
$314.00
+33.7%
01/30/2026
Last report
Oct 29, 2026
Fiscal period
Q1 2027
$2.91 / $2.67
+8.86%beat
Revenue / Est. (USD)
1.41B / 1.39B
+1.55%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.42B
1.43B
1.46B
1.41B
Cost of goods sold
536.28M
532.58M
594.13M
536.45M
Cost of revenue
536.28M
532.58M
594.13M
536.45M
Research and development expenses
90.97M
94.27M
105.72M
101.53M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
275.70M
279.80M
293.36M
284.20M
Operating expense
386.24M
393.16M
417.88M
385.73M
Total operating expenses
922.51M
925.74M
1.01B
922.18M
Operating income
500.30M
505.67M
451.64M
492.64M
Other non operating income
42.00K
181.00K
4.40M
2.95M
EBT including unusual items
496.15M
502.31M
474.16M
539.16M
EBT excluding unusual items
504.48M
518.30M
476.09M
511.31M
Income tax expense
103.56M
103.58M
90.73M
120.74M
Effective tax rate
20.87%
20.62%
19.14%
22.39%
Other operating expenses
-
-
-
-
Net income
392.59M
398.73M
383.43M
418.41M
Net profit margin
27.59%
27.86%
26.20%
29.57%
Earnings per share
2.81
0.29
0.30
0.29
Interest and investment income
4.46M
3.80M
31.76M
21.20M
Interest expense
-
-
-
-4.81M
Net interest expenses
4.46M
3.80M
31.76M
16.38M
Depreciation and amortization charges
-
-
-
-
EBITDA
543.79M
558.22M
490.13M
534.38M
Gain or loss from assets sale
-
-
-
-61.78M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps